NCT01405131View on ClinicalTrials.gov

A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2012

Primary Completion Date

February 20, 2012

Study Completion Date

February 20, 2012

Conditions
Therapeutic Equivalency
Interventions
DRUG

methylprednisolone

constituted powder for oral suspension 4 mg/mL single dose at 32 mg

DRUG

methylprednisolone

tablets 32 mg single dose

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01405131 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets | Biotech Hunter | Biotech Hunter